CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy.
作者信息
Jain Swati, Ma Kevin, Morris Luc G T
机构信息
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Transl Cancer Res. 2023 Feb 28;12(2):447-451. doi: 10.21037/tcr-22-2880. Epub 2023 Feb 21.
Abstract
摘要
相似文献
1
CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy.
Transl Cancer Res. 2023 Feb 28;12(2):447-451. doi: 10.21037/tcr-22-2880. Epub 2023 Feb 21.
2
Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer.
Cancer. 2012 Mar 15;118(6):1726-37. doi: 10.1002/cncr.26456. Epub 2011 Aug 25.
3
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
4
Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.
BMC Med. 2022 Apr 12;20(1):120. doi: 10.1186/s12916-022-02315-2.
5
Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome.
Lung Cancer. 2013 Jul;81(1):130-7. doi: 10.1016/j.lungcan.2013.03.003. Epub 2013 Mar 26.
6
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
7
[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.
8
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.
9
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5.
10
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Front Immunol. 2020 Jun 10;11:1173. doi: 10.3389/fimmu.2020.01173. eCollection 2020.
引用本文的文献
1
Inhibition and evasion of neutrophil microbicidal responses by .
mBio. 2025 Feb 5;16(2):e0327424. doi: 10.1128/mbio.03274-24. Epub 2024 Dec 16.
2
Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival.
Clin Transl Immunology. 2024 Jul 18;13(7):e1522. doi: 10.1002/cti2.1522. eCollection 2024.
本文引用的文献
1
Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer.
Cancers (Basel). 2022 Aug 9;14(16):3846. doi: 10.3390/cancers14163846.
2
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.
J Thorac Oncol. 2022 Aug;17(8):991-1001. doi: 10.1016/j.jtho.2022.04.009. Epub 2022 Apr 28.
3
Neutrophils in the era of immune checkpoint blockade.
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2020-002242.
4
Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress.
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-23. doi: 10.1200/EDBK_321483.
5
Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance.
Front Immunol. 2020 Sep 2;11:2100. doi: 10.3389/fimmu.2020.02100. eCollection 2020.
6
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.
Clin Cancer Res. 2020 Aug 15;26(16):4360-4368. doi: 10.1158/1078-0432.CCR-20-0175. Epub 2020 Apr 6.
7
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC.
JCI Insight. 2019 Dec 19;4(24):130850. doi: 10.1172/jci.insight.130850.
8
Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
Front Immunol. 2019 Sep 20;10:2155. doi: 10.3389/fimmu.2019.02155. eCollection 2019.
9
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
JAMA Oncol. 2019 Aug 1;5(8):1195-1204. doi: 10.1001/jamaoncol.2019.1549.
10
The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.
Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE.
Zotero 插件